Breast Cancer

, Volume 22, Issue 4, pp 432–436 | Cite as

HER-2 positive primary solid neuroendocrine carcinoma of the breast: a case report and review of the literature

  • Guler Yavas
  • Pinar Karabagli
  • Murat Araz
  • Cagdas Yavas
  • Ozlem Ata
Case Report

Abstract

Primary pure neuroendocrine carcinoma of the breast is an extremely rare tumor. We report a case of primary solid neuroendocrine carcinoma in a 77-year-old postmenopausal woman who was admitted to the hospital with masses on her right breast and axillary region. Radical mastectomy with axillary lymph node resection was performed. Immunohistochemical stainings of the tumor cells with synaptophysin, GCDFP-15, estrogen, progesterone, and c-erbB-2 were positive. Five of 16 lymph nodes were metastatic. She did not receive adjuvant chemotherapy. After 15 months of follow-up she is free of the disease. Literature review revealed that this is the second case of HER-2 positive primary neuroendocrine tumor of the breast.

Keywords

Breast Carcinoma c-erbB-2 Neuroendocrine Tumor 

References

  1. 1.
    Ellis IO, Schnitt SJ, Sastre-Garau X. Invasive breast carcinoma. In: Tavassoli FA, Devilee P, editors. WHO classification of tumors. Pathology and genetics of tumors of the breast and female genital organ. Lyon: IARC; 2003. p. 13–59.Google Scholar
  2. 2.
    Feyrter F, Hartmann G. On the carcinoid growth form of the carcinoma mammae, especially the carcinoma solidum (Gelatinosum) mammae. Frankf Z Pathol. 1963;73:24–39.PubMedGoogle Scholar
  3. 3.
    Lack EE, Cubilla AL, Woodruff JM, Farr HW. Paragangliomas of the head and neck region: a clinical study of 69 patients. Cancer. 1977;39(2):397–409.PubMedCrossRefGoogle Scholar
  4. 4.
    Wick, NLR. Neuroendocrine neoplasia: an overview of current concepts and terminology. Alexandria: American Society of Clinical Oncology; 1994. p. 246–248.Google Scholar
  5. 5.
    Richardson RL, Weiland LH. Undifferentiated small cell carcinomas extrapulmonary sites. Semin Oncol. 1982;9:484–96.PubMedGoogle Scholar
  6. 6.
    Kanthan R, Negreiros F, Kanthan SC. Colonic carcinoid metastatic to the breast. Arch Pathol Lab Med. 2003;127:1373–5.PubMedGoogle Scholar
  7. 7.
    Kelly C, Henderson D, Corris P. Breast lumps: rare presentation of oat cell carcinoma of lung. J Clin Pathol. 1988;41:171–2.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Akhtar K, Zaheer S, Ahmad SS, Hassan MJ. Primary neuroendocrine carcinoma of the breast. Indian J Pathol Microbiol. 2009;52:71–3.PubMedCrossRefGoogle Scholar
  9. 9.
    Yaren A, Kelten C, Akbulut M, Teke Z, Duzcan E, Erdem E. Primary neuroendocrine carcinoma of the breast: a case report. Tumori. 2007;93:496–8.PubMedGoogle Scholar
  10. 10.
    Stita W, Trabelsi A, Gharbi O, Mokni M, Korbi S. Primary solid neuroendocrine carcinoma of the breast. Can J Surg. 2009;52:289–90.Google Scholar
  11. 11.
    Zhang J, Hen W. Bilateral primary breast neuroendocrine carcinoma in a young woman: report of a case. Surg Today. 2011;41:1575–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Fujimoto Y, Yagyu R, Murase K, Kawajiri H, Ohtani H, Arimoto Y, et al. A case of solid neuroendocrine carcinoma of the breast in a 40-year-old woman. Breast Cancer. 2007;14:250–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Lopez-Bonet E, Alonso-Ruano M, Barraza G, Martin A, Bernado L, Menendez JA. Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling. Oncol Rep. 2008;20:1369–74.PubMedGoogle Scholar
  14. 14.
    Upalakalin JN, Collins LC, Tawa N, Parangi S. Carcinoid tumors in the breast. Am J Surg. 2006;191:799–805.PubMedCrossRefGoogle Scholar
  15. 15.
    Richter-Ehrenstein C, Arndt J, Buckendahl A, Eucker J, Weichert W, Kasajima A, et al. Solid neuroendocrine carcinomas of the breast. Metastases or primary tumors? Breast Cancer Res Treat. 2010;124(2):413–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Makretsov N, Gilks CB, Coldman AJ, Hayes M, Huntsman D. Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol. 2003;34:1001–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Horiguchi S, Hishima T, Hayashi Y, Shiozawa Y, Horiguchi K, Kuroi K, et al. HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma. J Med Dent Sci. 2010;57:155–63.PubMedGoogle Scholar
  18. 18.
    Bartlett JM, Going JJ, Mallon EA, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol. 2001;195:422–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Hanna W, Kahn HJ, Andrulis I, et al. Distribution and patterns of staining of Neu oncogene product in benign and malignant breast diseases. Mod Pathol. 1990;3:455–61.PubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2012

Authors and Affiliations

  • Guler Yavas
    • 1
  • Pinar Karabagli
    • 2
  • Murat Araz
    • 3
  • Cagdas Yavas
    • 4
  • Ozlem Ata
    • 3
  1. 1.Department of Radiation Oncology, Selcuklu Faculty of MedicineSelcuk UniversityKonyaTurkey
  2. 2.Department of Pathology, Selcuklu Faculty of MedicineSelcuk UniversityKonyaTurkey
  3. 3.Department of Medical Oncology, Selcuklu Faculty of MedicineSelcuk UniversityKonyaTurkey
  4. 4.Department of Radiation OncologyKonya Training and Research HospitalKonyaTurkey

Personalised recommendations